The Australian government revealed in a surprise announcement Friday that MDMA and psychedelic mushrooms will soon be medically available for patients with post-traumatic stress disorder and treatment-resistant depression , respectively.

The decision follows numerous international studies that point to the promise of magic mushrooms, also known as psilocybin, and MDMA, otherwise known as ecstasy or molly, for alleviating mental health issues . Prescriptions will start in Australia on July 1.

The Therapeutic Goods Administration clarified that only authorized psychiatrists will be able to dole the substances out, and only for patients whose depression or PTSD have proven resistant to traditional treatment and standard medication.

The decision acknowledges the current lack of options for patients with specific treatment-resistant mental illnesses, the administration wrote in a statement on its website. It means that psilocybin and MDMA can be used therapeutically in a controlled medical setting.